Leadership & Pay ·
PDS Biotechnology Corporation filed a Form 8-K to update its corporate presentation deck as of September 21, 2026
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation filed a Form 8-K to update its corporate presentation deck as of September 21, 2026. The filing highlights the company's strategic refocus on PDS0301 and notes that proceeds from a September 2026 financing led by Nant Capital enabled Dr. Patrick Soon-Shiong to join the Board of Directors. The presentation details clinical data for PDS0301 in metastatic colorectal cancer, including a 71.4% response rate at six months and approximately 80% 24-month survival. It also outlines ongoing trials for PDS0101 in HPV-positive head and neck cancer and mentions an additional financing tranche committed upon submission of a registrational Phase 3 protocol for PDS0301 to the FDA. PDS Biotechnology Corporation operates in the biotechnology industry, developing tumor-targeted immunotherapies for solid tumors.